Article Text

other Versions

PDF
New aspects on patients affected by dysferlin deficient muscular dystrophy
  1. Lars Klinge (lars.klinge{at}med.uni-goettingen.de)
  1. University Medical Centre Göttingen, Germany
    1. Ahmed Aboumousa
    1. University of Newcastle, Institute of Human Genetics, United Kingdom
      1. Michelle Eagle
      1. University of Newcastle, Institute of Human Genetics, United Kingdom
        1. Judith Hudson
        1. University of Newcastle, Institute of Human Genetics, United Kingdom
          1. Anna Sarkozy
          1. University of Newcastle, Institute of Human Genetics, United Kingdom
            1. Gianluca Vita
            1. University of Newcastle, Institute of Human Genetics, United Kingdom
              1. Richard Charlton
              1. University of Newcastle, Institute of Human Genetics, United Kingdom
                1. Mark Roberts
                1. Greater Manchester Neurosciences Centre, United Kingdom
                  1. Volker Straub
                  1. University of Newcastle, Institute of Human Genetics, United Kingdom
                    1. Rita Barresi
                    1. University of Newcastle, Institute of Human Genetics, United Kingdom
                      1. Hanns Lochmüller
                      1. University of Newcastle, Institute of Human Genetics, United Kingdom
                        1. Kate Bushby (kate.bushby{at}ncl.ac.uk)
                        1. University of Newcastle, Institute of Human Genetics, United Kingdom

                          Abstract

                          Mutations in the dysferlin gene lead to limb-girdle muscular dystrophy 2B, Miyoshi Myopathy and distal anterior compartment myopathy. We here describe a cohort of 36 patients affected by dysferlinopathy in the first UK study of clinical, genetic, pathological, and biochemical data. The diagnosis was established by reduction of dysferlin in the muscle biopsy and subsequent mutational analysis of the dysferlin gene. 17 mutations were novel; the majority of mutations were small deletions/insertions, and no mutational hotspots were identified. 61% of patients (22 patients) initially presented with LGMD2B, 31% (11 patients) with a Miyoshi phenotype, one patient with proximodistal mode of onset, one patient with muscle stiffness after exercise, and one patient as a symptomatic carrier. A wider range of age of onset was noted than previously reported with 25% of patients having first symptoms before the age of 13 years. Independent of the initial mode of presentation, in our cohort of patients the gastrocnemius muscle was the most severely affected muscle leading to an inability to stand on tiptoes, and lower limbs were affected more severely than upper limbs.

                          As previous anecdotal evidence on patients affected by dysferlinopathy suggests good muscle prowess before onset of symptoms, we also investigated pre-symptomatic fitness levels of the patients. 53% of the patients were very active and sporty before onset of symptoms which makes the clinical course of dysferlinopathy unusual within the different forms of muscular dystrophy and provides a challenge to understanding the underlying pathomechanisms in this disease.

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.